BOSTON--(BUSINESS WIRE)--BioBright, a data and analytics company unlocking the potential of unstructured clinical and research information, today announced that Dr. Edward Chung has joined the organization as Chief Medical Officer. A practicing physician, Dr. Chung brings experience as a Chief Medical Information Officer in the hospital and software industry to BioBright, where he will be leading engagements with medical device companies and health systems as well as continuing to advance BioBright’s technology to meet the needs of clinical end users.
With proven ability to securely gather, analyze, and present data from multiple structured and unstructured data sources in the biopharmaceutical market, BioBright is well positioned to offer substantial new information and benefits to its clinical collaborators and end users.
“We are at a critical point in healthcare where data entry, user interfaces, and other aspects of technology threaten to totally upend the care dynamic, keeping clinicians away from patients’ bedsides and instead trapping them in front of screens and keyboards” said Dr. Chung. “All too often clinicians and their patients feel the pain of technology but don’t see proportional benefits to their daily work and care. I believe that companies like BioBright hold the keys to making technology work for — not against — care teams and their patients. As an industry, we must succeed at this challenge.”
“Dr. Chung brings deep and real world experience to our organization, it is a rare combination to find someone with both clinical and software expertise. I’m excited to work with Ed to bring BioBright’s cutting-edge technology to healthcare professionals. His appointment is a milestone for our company, and I’m excited to show how our technology will drive tangible improvements in the industry” said Charles Fracchia, CEO of BioBright.
BioBright is a privately owned data and analytics company in Boston, MA, where it began operations in 2015. BioBright’s technology enables biomedical companies to securely and privately collect and analyze data at scale. Initially funded by DARPA, the company is now deploying with leading biomedical companies, including four on the Fortune 500 list.